ImmunityBio (NASDAQ: IBRX)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-11-11 | ||||||
REV |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-30 | ||||||
REV |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of ImmunityBio (NASDAQ: IBRX) through any online brokerage.
Other companies in ImmunityBio’s space includes: Zentalis Pharmaceuticals (NASDAQ:ZNTL), Day One Biopharmaceutical (NASDAQ:DAWN), Xencor (NASDAQ:XNCR), Ligand Pharmaceuticals (NASDAQ:LGND) and Relay Therapeutics (NASDAQ:RLAY).
The latest price target for ImmunityBio (NASDAQ: IBRX) was reported by Jefferies on Wednesday, August 3, 2022. The analyst firm set a price target for 8.00 expecting IBRX to rise to within 12 months (a possible 75.82% upside). 1 analyst firms have reported ratings in the last year.
The stock price for ImmunityBio (NASDAQ: IBRX) is $4.55 last updated August 16, 2022, 8:00 PM UTC.
There are no upcoming dividends for ImmunityBio.
ImmunityBio’s Q3 earnings are confirmed for Friday, November 11, 2022.
There is no upcoming split for ImmunityBio.
ImmunityBio is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.